FORMAC announces the appointment of new R&D Director
FORMAC Pharmaceuticals N.V. announced today the appointment of Michiel Van Speybroeck, PhD as new R&D Director.
During his academic career at the University of Leuven (Belgium), Michiel has been at the forefront of the research on mesoporous silicates for the delivery of poorly soluble drugs. His findings have delivered new and useful insights into the relationship between silica properties and formulation performance. He has published extensively on the topic, in internationally reviewed journals as well as in handbooks. He also holds experience with conventional formulation approaches, most notably amorphous solid dispersions and lipid based formulations. Michiel has received several scientific awards, including the award in Drug Formulation Design and Development from the American Association of Pharmaceutical Scientists.
Michiel obtained his Master’s degree in pharmaceutical sciences from the Ghent University (Belgium) and holds a PhD in pharmaceutical sciences from the University of Leuven (Belgium). He has spent several months of his academic career at foreign research institutions, including the Utrecht University (The Netherlands) and the Monash Institute of Pharmaceutical Sciences (Australia).
"We are very pleased with the opportunity to bring Michiel onto our Management team, with the number of internal and external developments coming to execution. We are very confident that Michiel will prove to be instrumental in transforming FORMAC Pharmaceuticals into a global leader in silica based drug delivery," stated Laurent Schueller, COO,CTO.